BRIEF-Sanofi, GSK Start New Phase 2 Study Of Adjuvanted Recombinant Protein-Based COVID-19 Vaccine Candidate

GlaxoSmithKline PLC: * GLAXOSMITHKLINE PLC - SANOFI AND GSK INITIATE NEW PHASE 2 STUDY

* GSK - IN PARALLEL, DEVELOPMENT WORK ON NEW SARS-COV-2 VARIANTS UNDERWAY * GSK - NEW PHASE 2 STUDY ASSESSES POTENTIAL FOR REFINED ANTIGEN FORMULATION TO ACHIEVE OPTIMAL IMMUNE RESPONSE, INCLUDING IN OLDER ADULTS

* GSK - IF RESULTS ARE POSITIVE, PHASE 3 STUDY TO START IN Q2 2021, WITH VACCINE EXPECTED TO BE AVAILABLE IN Q4 2021 * GSK - DEVELOPMENT WORK ON NEW SARS-COV-2 VARIANTS UNDERWAY

* GSK - SANOFI HAS COMMENCED DEVELOPMENT WORK AGAINST NEW VARIANTS WHICH WILL BE USED TO INFORM NEXT STAGES OF SANOFI/GSK DEVELOPMENT PROGRAMME. * GSK - IN PARALLEL, DEVELOPMENT WORK ON NEW SARS-COV-2 VARIANTS UNDERWAY Source text for Eikon: Further company coverage: